On the mechanism of anti-CD39 immune checkpoint therapy
With the coming of age of cancer immunotherapy, the search for new therapeutic targets has led to the identification of immunosuppressive adenosine as an important regulator of antitumor immunity. This resulted in the development of selective inhibitors targeting various components of the adenosiner...
Saved in:
| Main Authors: | John Stagg, Bertrand Allard, David Allard |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000186.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)
by: Sarah E. Conway, et al.
Published: (2025-07-01) -
Research progress of CD39-CD73-adenosine pathway in immune regulation of hepatocellular carcinoma
by: Lin SUN, et al.
Published: (2024-12-01) -
5-Aza-2′-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells
by: Adrian Fehn, et al.
Published: (2025-01-01) -
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells
by: Elias Brauneck, et al.
Published: (2025-04-01) -
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies
by: Djamila Chemlal, et al.
Published: (2025-12-01)